Glaucoma Drugs Market: Global Size, Trends, Competitive, Historical & Forecast Analysis 2028. Rise in prevalence of eye disorders such as Presbyopia, Macular Degeneration and Diabetic Retinopathy in the aging population and increase in Research & development for the improvement of novel entity are some of the key factors which boost the Global Glaucoma Drugs Market.
Glaucoma is inherited diseases that damage the eye’s optic nerve and can result in optic damage and vision loss. However, with early detection and treatment, you can often protect your eyes against serious vision loss.It is often related to a buildup of pressure inside your eye. Glaucoma be likely to hereditary and may not show up until later in life. The increased pressure, called intraocular pressure can damage the optic nerve. If the damage continues, Glaucoma can cause fatal vision loss. Lack of treatment for Glaucoma can cause total permanent blindness within a few years. There are two different types of glaucoma i.e., Open-Angle Glaucoma and Acute Angle-Closure Glaucoma. The most common type is Open-Angle Glaucoma with fewer common types including Closed-Angle Glaucoma and Normal-Tension Glaucoma. Open-Angle Glaucoma develops slowly over time and there is no pain. Closed-Angle Glaucoma can present slowly or quickly. The sudden presentation may cause severe eye pain, blurred vision, mid-dilated pupil, redness of the eye and nausea. Acute Angle-Closure Glaucoma is a less common form of Glaucoma that can rapidly impair vision. Glaucoma can be cured with eye drops, injections, oral pills, laser treatment and surgery. Though Glaucoma cannot be treated completely but the disease progression can be controlled with the help of available drugs like blockbuster drugs.
Global Glaucoma Drugs Market has been segmented on the basis of Disease Indication, Drug Class, End users, Surgery and Geography. On the basis of Disease Indication Global Glaucoma Drugs Market is classified as Closed Angle Glaucoma (CAG), Open Angle Glaucoma (OAG), Secondary Glaucoma, and Congenital Glaucoma and other. On the basis of Drug Class Global Glaucoma Drugs market is segmented into Prostaglandin Analogs (PGAS), Alpha Agonist, Beta Blockers, Cholinergic Drugs and others. On the basis of end users Global Glaucoma Drugs market is segmented into Hospitals and Home users. On the basis of surgery Global Glaucoma Drugs market is classified into Laser Iridology, Laser Trabeculoplasty, Aqueous Shunt Surgery, Peripheral Iridotomy and Others.
The regions covered in Global Glaucoma Drugs market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Glaucoma Drugs market research reports cover prominent players are,
North America, US, Mexico, Chily, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, South Korea, Japan, India, Southeast Asia, Latin America, Brazil, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa
Rising prevalence of diabetes, increasing geriatric populationas well as expanding health care spending is the major key driver forGlobal Glaucoma Drugs Market. Along with growing obese population will boost the market growth in the upcoming years. Development of new drugs & devices and drug therapy focused upon Intraocular Pressure(IOP) are some notable market trends. However, high cost of treatment, severe side effects and hasty drug approval processes act as a major roadblock for the market growth.
However, low efficacy of generic drugs restricts the Ophthalmologists in prescribing generic drugs over branded drugs in developed countries. It has been seen that generic drugs show different bioequivalence with change in temperature. In addition to this bottle’s material, shape &size, delivery dose, drop size and different pH also affects the efficacy of generic drug, ensuing more number of side effects and longer duration treatment.
The easy availability of medical insurance coverage for treatment and diagnosis is likely to create worthwhile opportunities for the key players operating in the Global Glaucoma Drugs Market in the coming years.
The advancements in drug development and the investigation of a large number of regulatory healthcare reforms, favoring development of methods for the improved diagnosis and treatment of chronic pain, will help the Global Glaucoma Drugs Market along a promising growth path in the future.
According to the research report, the North America is expected to show a strong growth in the next few years, due to the rising geriatric population and the availability of options for treatment of eye disorders such as cataract, age-related muscular degeneration, glaucoma, diabetic retinopathy, and others.Furthermore, the increasing awareness among patients regarding Glaucoma and the introduction of favorable reimbursement policies are some of the chief factors predicted to fuel the growth of the North America glaucoma therapeutics market in the next few years.
Moreover, Europe is expected to show a healthy growth rate during the forecast period. The considerable growth of this region can be attributed to the growing demand for topical eye drops and expected launch of the combination medication. Asia Pacific is projected to witness fastest growth with a profitable CAGR during the forecast period due to high clinical requirements, rising income, accessibility of effective treatment methods and rising awareness about early diagnosis in emerging countries. It was stated that around two-third of the population in the Asia Pacific region are blind or vision impaired. Besides, development of various novel technologies in developing markets such as China & India is projected to expand the healthcare facilities.
|Forecast Period||2022 - 2028|
|Market Size in 2020:||XX|
|Base year considered||2021|
|Forecast Period CAGR %:||
|Market Size Expected in 2028:||XX|
|Tables, Charts & Figures:||175|
|Aerie Pharmaceuticals,Allergan plc, Bausch & Lomb Incorporated, Inotek Pharmaceuticals, Merck & Co. Inc., Pfizer Inc., Fera Pharmaceuticals, Allergan, pSivida Corp, Icon Bioscience Inc, Amorphex Therapeutics LLC., Ellex, Quantel, Lumenis, ACADIA Pharmaceuticals, Cipla Inc, AbbVie, Akorn operating company LLC, Novartis AG, Santen Pharmaceutical Co., Ltd., SIFI S.p.A, F. Hoffmann-La Roche, Ltd., HOYA Corp., Bayer AG, and others.|
By Disease Indication Analysis, By Drug Class Analysis, By Surgery Analysis, By End users Analysis
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|